Quanterix is on a mission to change the way in which healthcare is provided by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come.
The Quanterix flagship technology, the SIngle MOlecule Array (Simoa) is an ultra-sensitive immunoassay technology that allows detection of proteins and nucleic acids at lowest possible levels. This gives researchers the ability to examine critical biomarkers, even at baseline levels in most common sample types. Using the fully automated HD-X instrument, it is possible to measure up to six biomarkers in a single sample with high reproducibility.